All In Biotech

Drug Trial Radar · NCT07712692

Evaluation of NWRD09 for HPV-16 Related Cervical HSIL

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD09 in Patients With HPV16-Positive Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

Jun 30, 2027

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16.

Conditions

  • High-grade Squamous Intraepithelial Lesion (HSIL)

Interventions

  • NWRD09 InjectionBiological

    NWRD09 administered by intramuscular injection at weeks 0, 2, 4, and 12.

  • NWRD09 PlaceboBiological

    Placebo administered by intramuscular injection at weeks 0, 2, 4, and 12.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with Histopathological Regression of Cervical Lesions to non-HSIL (LSIL/CIN1 or no lesion) at week 24.Time frame: Week24

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Dalian Maternal and Child Health Hospital

    Dalian, China

  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The First Hospital Affiliated to AMU (SOUTHWEST HOSPITAL)

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Maternity and Child-care Hospital / Gansu Provincial central Hospital

    Lanzhou, Gansu, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Nanjing Maternity and Child Health Care Hospital

    Nanjing, Jiangsu, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shanxi Maternal and Child Health Hospital

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.